Faculty of Pharmacy, Department of Pharmacology & Toxicology, Minia University, Minia 61511, Egypt.
Faculty of Pharmacy, Department of Pharmacology & Toxicology, Al-Azhar University, Assiut 71524, Egypt.
Biomed Pharmacother. 2017 Nov;95:529-535. doi: 10.1016/j.biopha.2017.08.121. Epub 2017 Sep 12.
Liver is the largest internal organ concerning with metabolism, hormonal balance and clarifying of the toxins. One of the main complications of methotrexate (MTX) therapy was the hepatic injury.
This study was conducted to elucidate the possible protective effects of phloridzin (PHL) against MTX-induced hepatotoxicity as compared to standard agent N-acetylcysteine (NAC).
Rats were randomly divided into a normal control group, a respective group (PHL 40mg/kg/day orally (p.o.) for 10 consecutive days), a hepatotoxicity control group (MTX 20mg/kg, i.p., once), and three treated groups received NAC (150mg/kg/day; a reference standard), PHL (40mg/kg/day) and PHL (80mg/kg/day) p.o. for 10 consecutive days, at the end of the day 3 of the experiment rats were administered MTX. Assessed biomarkers included serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) as liver function parameters, serum tumor necrosis factor-α (TNF-α) and cyclooxygenase-II (COX-II), as inflammatory biomarkers, hepatic total antioxidant capacity (TAC), thiobarbituric acid reactive substances (TBARS), glutathione reduced (GSH), nitrite (NO), catalase (CAT), glutathione-S-transferase (GST) and superoxide dismutase (SOD) as oxidative stress biomarkers. Furthermore, hepatic caspase-3 expression was assessed. Biochemical and molecular estimations reinforced by histopathological findings.
Rats pre-treated with PHL significantly reduced hepatic injury, evidenced by significant reductions in ALT, AST and LDH, TNF-α and COX-II levels, significant reductions in hepatic NO and TBARS levels, and significant elevations in hepatic TAC, GSH, GST, CAT and SOD levels. Additionally, downregulation of hepatic caspase-3 expression. Finally, histopathological results consistent with our previous findings.
PHL protects against hepatic injury in rats mainly through mitigation of oxidative stress, inflammation and apoptosis in hepatic tissues and may be promising to alleviate and early treatment of MTX-induced hepatoxicity in man.
肝脏是与新陈代谢、激素平衡和毒素清除有关的最大的内部器官。甲氨蝶呤 (MTX) 治疗的主要并发症之一是肝损伤。
本研究旨在探讨根皮苷 (PHL) 相对于标准药物 N-乙酰半胱氨酸 (NAC) 对 MTX 诱导的肝毒性的可能保护作用。
大鼠随机分为正常对照组、相应组 (PHL 40mg/kg/天,口服,连续 10 天)、肝毒性对照组 (MTX 20mg/kg,腹腔注射,一次) 和三个治疗组,分别给予 NAC (150mg/kg/天;参考标准)、PHL (40mg/kg/天) 和 PHL (80mg/kg/天) 口服,连续 10 天,实验第 3 天结束时给予 MTX。评估的生物标志物包括血清丙氨酸氨基转移酶 (ALT)、天冬氨酸氨基转移酶 (AST) 和乳酸脱氢酶 (LDH) 作为肝功能参数,血清肿瘤坏死因子-α (TNF-α) 和环氧化酶-II (COX-II),作为炎症生物标志物,肝总抗氧化能力 (TAC)、硫代巴比妥酸反应物质 (TBARS)、还原型谷胱甘肽 (GSH)、亚硝酸盐 (NO)、过氧化氢酶 (CAT)、谷胱甘肽-S-转移酶 (GST) 和超氧化物歧化酶 (SOD) 作为氧化应激生物标志物。此外,还评估了肝组织中的半胱天冬酶-3 表达。通过组织病理学发现,生化和分子估算得到了加强。
用 PHL 预处理的大鼠肝损伤明显减轻,表现为 ALT、AST 和 LDH 水平显著降低,TNF-α 和 COX-II 水平显著降低,肝 NO 和 TBARS 水平显著降低,肝 TAC、GSH、GST、CAT 和 SOD 水平显著升高。此外,肝半胱天冬酶-3 表达下调。最后,组织病理学结果与我们之前的发现一致。
PHL 通过减轻肝组织中的氧化应激、炎症和细胞凋亡来保护大鼠免受肝损伤,可能有希望缓解和早期治疗人类 MTX 诱导的肝毒性。